Lifibrol

This classification denotes an anti-lipidemic agent with the molecular formula C21H26O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6KWX9X0Q5K, chemically known as benzoic acid, 4-(4-(4-(1,1-dimethylethyl)phenyl)-2-hydroxybutoxy)-, (+-)- but generally known as lifibrol, which bears US NIH Compound Identifier 57112. European Medicines Agency schedules Lifibrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08512MIG. The term LIFIBROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). LIFIBROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lifibrol under HS 29189900 and SITC 51396. As of Q4 2014, LIFIBROL remains the US FDA Preferred Term for this commodity. Lifibrol bears US NLM identifiers UMLS ID C0125829 and NCI Concept Code C82244. SMILES: OC(CCc1ccc(C(C)(C)C)cc1)COc1ccc(cc1)C(=O)O.